Will Johnson & Johnson (JNJ) Q2 MedTech revenue be above $8.9B? Odds jumped to 100% on Jul 15, 2026

ResolvedOutcome: YesMove

Will Johnson & Johnson (JNJ) Q2 MedTech revenue be above $8.9B? On , the market’s odds jumped from 52.5¢ to 100¢ (+47.5 pts) within an hour of an AI-matched news signal from livesquawk. The market has since resolved Yes.

How did the odds move?

At match52.5¢
+5m52.5¢
+30m100¢
+1h100¢
1h move+47.5 pts

Yes-side prices at the moment the news was matched and at the stamped impact windows after it. Windows the tracker could not measure inside its honesty band are omitted, never estimated.

What moved the odds?

Yeslivesquawk99%match
$JNJ Johnson & Johnson Q2 2026 Earnings • -Adj EPS $2.90 (est $2.85) • -Sales $25.31B (est 25.04B) • -Medtech Sales $8.93b (est $8.99b) • -Medicine Revenue $16.38b (est $16.12b) • -Sees FY Sales $100.88 To $101.48, Saw $100.3b To $101.3b • -Sees FY Adj EPS $11.60 To $11.75, Saw $11.45 To $11.65 • Sees FY Sales $100.8b To $101.4b, Saw $100.3b To $101.3b

Where does this market stand now?

This market has resolved Yes. Final market pricing put YES at 100%, as of .

YES100¢
NO0¢

Vol$2K

Follow this market

Will Johnson & Johnson (JNJ) Q2 MedTech revenue be above $8.9B? — live odds, order flow, and the full signal timeline.

See all outcomes for Will Johnson & Johnson (JNJ) Q2 MedTech revenue be above __? — the full event, with combined odds and signal timeline.